View More Recent Stories

Apr 11, 2016 07:00AM Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection
Apr 6, 2016 07:00AM Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference
Mar 30, 2016 07:05AM Summit Therapeutics (SMMT) Issues Positive Update on SMT C1100 Phase 1 in DMD
Mar 30, 2016 07:00AM Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
Mar 29, 2016 09:25AM Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence
Mar 15, 2016 07:00AM Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
Mar 7, 2016 07:23AM Ayretrade, Inc. (SUMM) Announces Presentation of Additional CoDIFy Phase 2 Data
Mar 7, 2016 07:00AM Summit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 Trial
Feb 29, 2016 07:35AM Summit Therapeutics Supports Ninth Annual Rare Disease Day
Feb 24, 2016 07:00AM Summit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing C. Difficile Toxins That Drive Disease Symptoms
Feb 17, 2016 07:00AM Summit Therapeutics to Participate in SunTrust Robinson Humphrey’s 2016 Orphan Drug Day
Feb 3, 2016 07:00AM Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
Jan 21, 2016 07:08AM Ayretrade, Inc. (SUMM) Announces Receipt of Regulatory Approval to Commence PhaseOut DMD
Jan 21, 2016 07:00AM Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
Jan 19, 2016 07:06AM Ayretrade, Inc. (SUMM) Granted Key European Patent for Ridinilazole for Treatment of C. Difficile
Jan 19, 2016 07:00AM Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection
Dec 17, 2015 07:00AM Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress
Dec 14, 2015 07:00AM Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2015 on 17 December 2015
Dec 10, 2015 07:00AM Summit Therapeutics to Participate in the JMP Securities DMD Forum
Dec 3, 2015 07:00AM Summit Therapeutics to Present at the 26th Annual Oppenheimer Healthcare Conference
Dec 2, 2015 07:00AM Summit Therapeutics Announces First Milestone Achieved in Strategic Alliance With University of Oxford for Future Generation Utrophin Modulators for Treatment of DMD
Nov 25, 2015 07:00AM Summit Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Conference
Nov 23, 2015 07:00AM Summit Therapeutics Announces Novel Antibiotic Ridinilazole (SMT19969) Achieves Statistical Superiority Over Vancomycin in CoDIFy Phase 2 Clinical Trial for C. difficile Infection
Nov 17, 2015 07:00AM Summit Therapeutics and the University of Oxford Announce Multi-Year Extension of Strategic Alliance for Development of Utrophin Modulators for DMD
Sep 30, 2015 07:00AM Summit Therapeutics Presents Additional Data From Phase 1b Modified Diet Clinical Trial of SMT C1100 in DMD Patients at WMS
Sep 24, 2015 07:00AM Summit Therapeutics to Present Phase 1b Clinical and Preclinical DMD Data at the 20th International Congress of the World Muscle Society
Sep 18, 2015 08:30AM Summit Therapeutics Presents New Positive Preclinical Data on Novel C. difficile Antibiotic SMT19969 at ICAAC 2015
Sep 10, 2015 07:00AM Summit Therapeutics Completes Targeted Enrolment for SMT19969 Phase 2 Trial for C. difficile Infection
Sep 2, 2015 07:00AM Summit Therapeutics Appoints Ralf Rosskamp, MD, as Chief Medical Officer
Aug 27, 2015 07:00AM Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2015 and Operational Progress
Aug 24, 2015 07:00AM Summit Therapeutics to Report Second Quarter 2015 Financial Results on 27 August 2015
Aug 17, 2015 07:00AM Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective in Duchenne Muscular Dystrophy
Jul 13, 2015 07:00AM Summit Therapeutics Publishes Preclinical Data on Disease-Modifying Potential of Utrophin Modulation in DMD
Jul 8, 2015 07:00AM Summit Therapeutics Receives FDA Fast Track Designation for Novel Antibiotic SMT19969 in the Treatment of C. difficile Infection
Jul 7, 2015 07:00AM Summit Therapeutics Granted Key Patent by European Patent Office for Utrophin Modulator SMT C1100 in the Treatment of DMD
Jun 19, 2015 07:00AM Summit Therapeutics to Present New Preclinical Data on Utrophin Modulator Programme at PPMD Connect Conference
Jun 15, 2015 07:00AM Summit to Present at JMP Securities Life Sciences Conference
Jun 11, 2015 07:00AM Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
Jun 5, 2015 07:00AM Summit Therapeutics to Report First Quarter 2015 Financial Results on 11 June 2015
May 6, 2015 07:34AM Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2015
May 1, 2015 02:00AM Summit Therapeutics Provides Notice of Full Year Financial Results
Apr 30, 2015 07:00AM Summit Therapeutics Granted Key Patent for Novel Antibiotic SMT19969 for the Treatment of C. Difficile Infection
Apr 7, 2015 07:00AM Summit to Present at Needham and Company's Annual Healthcare Conference
View More Recent Stories